JAGX supply chain intelligence for Jaguar Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Jaguar Health, Inc. (JAGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| STREETERVILLE-CAPITAL-LLC | STREETERVILLE-CAPITAL-LLC | 92% | the Company issued an aggregate of 54,222 shares of the Company’s common stock, par value $0.0001 (the “Common Exchange Shares”) to Streeterville in exchange for an aggregate of 7.96 outstanding shar… |
| UPTOWN-CAPITAL-LLC | UPTOWN-CAPITAL-LLC | 92% | the Company issued 500 shares of Series Q Perpetual Preferred Stock to Uptown in exchange for a $12,500,000 reduction in the outstanding balance of the December 2020 Royalty Interest |
| ALIVUS-LIFE-SCIENCES-LIMITED | ALIVUS-LIFE-SCIENCES-LIMITED | 90% | Napo's third-party contract manufacturer, India-based Alivus Life Sciences Limited (f/k/a Glenmark Life Sciences Limited) ('Alivus'), a research-driven, global, integrated pharmaceutical company, is … |
| ILIAD | ILIAD | 90% | the Company issued 22 shares of Series L Perpetual Preferred Stock (the “Series L Preferred Stock”) to Iliad |
| INVESTORS | INVESTORS | 90% | the Redemption Shares (as defined hereunder) that may, from time to time, be issued or become issuable to the Investors under the Preferred Stock Purchase Agreements |
| NAPO-PHARMACEUTICALS-INC | NAPO-PHARMACEUTICALS-INC | 90% | Napo is a wholly-owned subsidiary of the Company and receives payments from the License Agreement and Supply Agreement. |
| STREETERVILLE | STREETERVILLE | 90% | the Company issued 99.3822 shares of Series L Preferred Stock to Streeterville |
| INDENA-S-P-A | INDENA-S-P-A | 85% | Additionally, Napo is establishing a second processing site, which will be operated by Indena S.p.A. ('Indena'), a Milan, Italy-based contract manufacturer dedicated to the identification, developmen… |
| FUTURE-PAK-LLC | FUTURE-PAK-LLC | 80% | In connection with the License Agreement, Future Pak provides a limited guarantee of Licensee’s fulfillment of the milestone payments |
| RDHL | RedHill Biopharma Ltd. | 72% | Reciprocal relationship from RDHL graph: the marketed product from the market; · withdrawal of the therapeutic candidate from use in a clinical trial; · suspension or withdrawal of regulatory approva… |
| CHICAGO-VENTURE-PARTNERS-L-P | CHICAGO-VENTURE-PARTNERS-L-P | 70% | The Company received a gain on extinguishment of part of the debts owed to certain affiliates of Chicago Venture Partners, L.P. |
| CAPT | Captivision Inc | 62% | Reciprocal relationship from CAPT graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAPT graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAPT g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INSTITUTIONAL-INVESTOR | INSTITUTIONAL-INVESTOR | 92% | the shares of Common Stock to be sold and issued by the Company to the Institutional Investor under the ELOC Agreement |
| WOODWARD | WOODWARD | 92% | Our future revenue stream will substantially come from one customer, Woodward, and will solely be dependent on that certain manufacturing and supply agreement, dated January 12, 2026, by and among Na… |
| NAPO-PHARMACEUTICALS-INC | NAPO-PHARMACEUTICALS-INC | 90% | On March 6, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note A… |
| WOODWARD-SPECIALTY-LLC | WOODWARD-SPECIALTY-LLC | 90% | Woodward purchases existing product inventory from Napo pursuant to the terms of the manufacturing and supply agreement. |
| CAH | Cardinal Health, Inc. | 85% | s promise to transfer Mytesi to specialty pharmacies based on specified payment and shipping terms as outlined in the Exclusive Distribution Agreement entered into by the Company and Cardinal Health,… |
| CAH | Cardinal Health, Inc. | 85% | Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAH graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from CAH grap… |
| FUTURE-PAK-LLC | FUTURE-PAK-LLC | 80% | Future Pak is an affiliate of Woodward and is a party to the manufacturing and supply agreement with Napo. |
| IRWD | Ironwood Pharmaceuticals, Inc. | 72% | suant to Chapter 34 Table of Contents 11 of the US Bankruptcy Code. The rights to crofelemer and the botanical extract used in Equilevia and Neonorm, as well as other intellectual property rights, we… |
| IRWD | Ironwood Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IRWD graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from JAGX graph: suant to Chapter 34 Table of Conten… |
| RDHL | RedHill Biopharma Ltd. | 72% | Reciprocal relationship from RDHL graph: (Prevacid ® ) and branded and generic, prescription and OTC esomeprazole magnesium (Nexium ® ). Prescription dexlansoprazole (Dexilant ®, marketed by Takeda P… |
| COMPANY-NAPO-NAPO-ACQUISITION-CORPORATION | COMPANY-NAPO-NAPO-ACQUISITION-CORPORATION | 62% | fficient to allow Napo to sell its products at a profit. Healthcare Reform A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and other third-part… |
| E-LLC | E-LLC | 62% | fficient to allow Napo to sell its products at a profit. Healthcare Reform A primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and other third-part… |
| GLENMARK-LIFE-SCIENCES-LIMITED | GLENMARK-LIFE-SCIENCES-LIMITED | 62% | . We are not aware of any FDA-approved drugs specifically acting as anti-secretory drugs to improve stool consistency. ORS, with or without antibiotics, is the current standard of care for infectious… |
| INDIA-BASED-ALIVUS-LIFE-SCIENCES-LIMITED | INDIA-BASED-ALIVUS-LIFE-SCIENCES-LIMITED | 62% | . We are not aware of any FDA-approved drugs specifically acting as anti-secretory drugs to improve stool consistency. ORS, with or without antibiotics, is the current standard of care for infectious… |
| PATHEON-PHARMACEUTICALS-INC | PATHEON-PHARMACEUTICALS-INC | 62% | ondition and location. Inventory is categorized into raw materials, work-in-process, and finished goods. Raw materials consist of CPL, recognized as inventory upon harvest and valued at cost, includi… |
| STREETERVILLE-CAPITAL-LLC | STREETERVILLE-CAPITAL-LLC | 62% | or any of our partners. Our future revenue stream will only come from one customer, Woodward, and will solely be dependent on the Manufacturing and Supply Agreement (as defined hereunder) with Woodwa… |
| UNITED-KINGDOM-BASED-VENTURE-LIFE-GROUP-PLC | UNITED-KINGDOM-BASED-VENTURE-LIFE-GROUP-PLC | 62% | phylaxis in adult solid tumor patients receiving targeted therapies with or without standard chemotherapy. As previously announced, the top line results from the OnTarget study showed that the trial … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| JAGX-DEBT-10414 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| JAGX-DEBT-10413 | Warrants outstanding: 9580 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| JAGX-DEBT | Debt stack $10.8M | 90% | Market cache reports total debt of $10.8M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| JAGX-OWNER-UBS-GROUP-AG | UBS Group AG | 90% | 13F overlay lists UBS Group AG as top holder; 12 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MCK | McKesson Corporation | 100.00 | 2 | |
| HRMY | Harmony Biosciences Holdings, Inc. | 100.00 | 2 | |
| MGNX | MacroGenics, Inc. | 100.00 | 2 | |
| IRWD | Ironwood Pharmaceuticals, Inc. | 100.00 | 1 | ['customer'] |
| APT | Alpha Pro Tech, Ltd. | 100.00 | 2 | |
| GRDN | Guardian Pharmacy Services, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| MASI | Masimo Corporation | 100.00 | 2 | |
| NEUP | Neuphoria Therapeutics Inc. | 100.00 | 2 | |
| RDHL | RedHill Biopharma Ltd. | 100.00 | 1 | ['customer', 'supplier'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer'] |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| ARDX | Ardelyx, Inc. | 100.00 | 2 | |
| CAPT | Captivision Inc | 100.00 | 1 | ['supplier'] |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| BNS | The Bank of Nova Scotia | 50.00 | 2 | |
| ADCT | ADC Therapeutics SA | 50.00 | 2 | |
| HROW | Harrow, Inc. | 50.00 | 2 | |
| HCSG | Healthcare Services Group, Inc. | 50.00 | 2 |